Abstracts tagged "Infection"

Abstract Number: 0098 • ACR Convergence 2021
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
Iulia Roman, Ioana Andreica, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…
Abstract Number: 0937 • ACR Convergence 2021
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Gino Chesini¹, Elizabeth Parrott¹, Lauren Fox¹, Jenna Beatty¹, Cassandra Effken¹, Na Yu¹, Florence Hosseini-Aslinia¹ and Megan Krause², ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
Abstract Number: 0141 • ACR Convergence 2021
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois¹, Ines Colmegna³, Carol Hitchon⁴, Louis Bessette⁵, Glen Hazlewood⁶, Carter Thorne⁷, Janet Pope⁸, Gilles Boire⁹, Diane Tin¹⁰, Edward Keystone¹¹, Vivian Bykerk¹², Susan Bartlett¹ and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York, NY, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…
Abstract Number: 0963 • ACR Convergence 2021
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
Gordon Lam¹, Andrew Laster², Sarah McCarter², Heather Gladue³, Ahmad Kashif², Erin Siceloff², Victoria Lackey³, Cheryl Robertson³, Ashley Toci² and Leonard Calabrese⁴, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in…
Abstract Number: 1558 • ACR Convergence 2021
Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study
Diana Villacis Nunez¹, Kaitlin Jones², Lucie Fan³, Whitney Moore², Aysha Jabbar², Matthew Oster⁴, Preeti Jaggi¹ and Sampath Prahalad⁵, ¹Emory University School of Medicine - Children's Healthcare of Atlanta, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine - Sibley Heart Center/Children's Healthcare of Atlanta, Atlanta, GA, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes…
Abstract Number: 0203 • ACR Convergence 2021
Chemoprophylaxis in Latent Tuberculosis Associated with Rheumatic Immune-mediated Diseases. Study of 240 Patients from a Single University Hospital
David Martinez-Lopez¹, Javier Rueda-Gotor¹, Joy Osorio-Chávez¹, Carmen Álvarez-Reguera¹, Virginia Portilla², Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tuberculosis (TB) may be increased with biologic therapy (BT). Diagnosis and treatment of latent TB infection (LTBI) is the best strategy to prevent TB.…
Abstract Number: 0965 • ACR Convergence 2021
Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup
Benjamin Naovarat¹, Francis Williams², Gloria Salazar³ and John Reveille⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²Specialists for Health/Wellmed, Shavano Park, TX, ³University of Texas Medical School at Houston/McGovern Medical School, Houston, TX, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There are concerns about using immunosuppressive agents for treatment of rheumatic diseases in patients with HIV infection due to concerns of opportunistic infection. We…
Abstract Number: 1655 • ACR Convergence 2021
Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
Lucia Cristina Dominguez Casas¹, Paz Rodriguez-Cundin², Trinidad Dierssen³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³University of Cantabria, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, Santadner, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed…
Abstract Number: 0204 • ACR Convergence 2021
Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents
Soo Min Ahn¹, Jonggi Choi², Byong Duk Ye², Suk-Kyun Yang², Ji Seon Oh³, Yong-Gil Kim², Chang-Keun Lee², Bin Yoo¹, Sang Hyoung Park² and Seokchan Hong², ¹ASAN MEDICAL CENTER, Seoul, South Korea, ²Asan Medical Center, Seoul, Republic of Korea, ³Asan Medical Center, Ulsan, Republic of Korea
Background/Purpose: Prophylactic anti-viral therapy is required in patients with hepatitis B virus (HBV) infection receiving biologics because of the high risk of HBV reactivation. However,…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
Abstract Number: 0252 • ACR Convergence 2021
Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis
Rajesh Kanumuri¹, Suma Balan², Vishal Marwaha², Sajitha Krishnan² and Pranav Chickermane², ¹Amrita Institute of Medical Sciences, Guntur, India, ²Amrita Institute of Medical Sciences, Kochi, India
Background/Purpose: Fever is the most common presentation of systemic juvenile idiopathic arthritis (SJIA) and it is difficult to predict whether the fever is due to…
Abstract Number: 0984 • ACR Convergence 2021
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Kevin Sheng-Kai Ma, Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philidelphia, PA
Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…
Abstract Number: 1684 • ACR Convergence 2021
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Andra R Bălănescu¹, Gustavo Citera², Virginia Pascual-Ramos³, Carol A Connell⁴, David Gold⁵, All-shine Chen⁴, Harry Shi⁶, Andrea B Shapiro⁷, Janet Pope⁸ and Hendrik Schulze-Koops⁹, ¹“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Peapack, NJ, ⁸University of Western Ontario, London, ON, Canada, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].